Experience

• Over the course of her career, Ms. Hasko has represented clients on a variety of significant transactions. Some of her experience includes advising:

  • Sonoma Biotherapeutics in its collaboration with Regeneron Pharmaceuticals to apply their scientific and clinical expertise and respective technology platforms to the discovery, development, and commercialization of novel regulatory T cell therapies for autoimmune diseases in a deal valued up to $120 million. The parties will focus on treatments for ulcerative colitis, Crohn’s disease and two other undisclosed indications, subject to an option for a fifth indication, and will equally co-fund research and development for all potential products and share equally any future commercial expenses and profits.
  • Daiichi Sankyo in a $6.9 billion oncology collaboration with AstraZeneca in 2019.
  • Novan in an exclusive license agreement with Sato Pharmaceutical to grant exclusive rights to develop and commercialize in Japan Novan's topical nitric oxide-releasing product candidate SB204, which was named a 2017 LMG Life Sciences Impact Case of the Year.
  • Juno Therapeutics in its landmark investment and collaboration with Celgene to develop CAR-T and TCR products, valued at more than US$1 billion. The transaction earned the Thomson Reuters Allicense 2015 Breakthrough Award and LMG Life Sciences Collaboration Impact Deal of the Year for 2015.
  • OncoMed in a collaboration with Celgene, valued at more than $3.3 billion, which received the In Vivo Alliance of the Year Award for 2013.
  • Prothena Biosciences and Neotope Biosciences in a license, development, and commercialization agreement with F. Hoffmann-La Roche and Hoffmann-La Roche, to develop and commercialize antibodies that target alpha-synuclein, including PRX002, Prothena's monoclonal antibody for the treatment of Parkinson's disease.
  • OncoMed in its collaboration with Bayer Schering Pharma, valued at more than $1.4 billion, which received the BayBio Pantheon 2010 DiNA Award.